Matrix metalloproteinase 2 as a biological marker in heart failure
- 15 May 2026
- journal article
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (2) , 13-21
Abstract
Heart failure (HF) is one of the major challenges in modern healthcare. Researches focused on new biological markers can significantly improve early detection and selection of effective therapeutic methods for patients with cardiovascular diseases (CVD). In recent years, matrix metalloproteinases (MMPs) are actively studied in cardiology. These proteolytic enzymes have stable structure. They are capable of breaking down peptide bonds in most extracellular matrix components. The objective of this review was to assess current experimental and clinical data on MMP-2 as a new diagnostic and prognostic marker in heart failure. MMP-2 is considered a key protease involved in heart remodeling. Elevated MMP-2 in the heart can lead to unfavorable ventricular remodeling and systolic heart dysfunction, even without other lesions. Clinical studies highlight significance of MMP-2 as a biomarker in diagnosis and prognosis of HF. Future research can provide more obvious data on feasibility of MMP-2 as a laboratory tool for diagnosing and assessing the risk in patients with HF. Further studies are also needed to explore the impact of MMP-2 inhibitors on morbidity and mortality in cardiovascular diseases.Keywords
This publication has 58 references indexed in Scilit:
- Association of Ventricular–Arterial Coupling with Biomarkers Involved in Heart Failure Pathophysiology – The STANISLAS CohortEuropean Journal of Heart Failure, 2024
- Proteomic Profiles of Left Atrial Volume and Its Influence on Response to Spironolactone: Findings from the HOMAGE Trial and STANISLAS CohortEuropean Journal of Heart Failure, 2024
- NKRF in Cardiac Fibroblasts Protects against Cardiac Remodeling Post‐Myocardial Infarction via Human Antigen RAdvanced Science, 2023
- Matrix metalloproteinase-2 proteolyzes mitofusin-2 and impairs mitochondrial function during myocardial ischemia–reperfusion injuryBasic Research in Cardiology, 2023
- MMP-2 and its implications on cardiac function and structure: Interplay with inflammation in hypertensionBiochemical Pharmacology, 2023
- Association Between MMP2 Gene Polymorphisms and Dilated Cardiomyopathy in a Chinese Han PopulationESC Heart Failure, 2023
- MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophinBiochemical Pharmacology, 2021
- Prolargin and Matrix Metalloproteinase-2 in Heart Failure after Heart Transplantation and Their Association with HaemodynamicsESC Heart Failure, 2019
- Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failureClinical Research in Cardiology, 2017
- Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failureAmerican Heart Journal, 2005